Literature DB >> 10632049

Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring?

J Borras1, A Scozzafava, L Menabuoni, F Mincione, F Briganti, G Mincione, C T Supuran.   

Abstract

Reaction of 20 aromatic/heterocyclic sulfonamides containing a free amino, imino, hydrazino or hydroxyl group, with 8-quinoline-sulfonyl chloride afforded a series of water-soluble (as hydrochloride or triflate salts) compounds. The new derivatives were assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA), and more precisely of three of its isozymes, CA I, II (cytosolic forms) and IV (membrane-bound form), involved in important physiological processes. Efficient inhibition was observed against all three isozymes, but especially against CA II (in nanomolar range), which is the isozyme known to play a critical role in aqueous humor secretion within the ciliary processes of the eye. Some of the best inhibitors synthesized were topically applied as 2% water solutions onto the eye of normotensive and glaucomatous albino rabbits, when strong and long-lasting intraocular pressure (IOP) lowering was observed with many of them. This result prompted us to reanalyze the synthetic work done by other groups for the design of water soluble, topically effective antiglaucoma sulfonamides. According to these researchers, the IOP lowering effect is due to the intrinsic nature of the specific heterocyclic sulfonamide considered, among which the thienothiopyran-2-sulfonamide derivatives represent the best studied case. Indeed, the first agents developed for such applications, such as dorzolamide, are derivatives of this ring system. In order to prove that the tail (in this case the 8-quinoline-sulfonyl moiety) conferring water solubility to a sulfonamide CA inhibitor is more important than the ring to which the sulfonamido group is grafted, we also prepared a dorzolamide derivative to which the 8-quinoline-sulfonyl moiety was attached. This new compound is quite water soluble as hydrochloride salt, behaves as a strong CA II inhibitor, and fared better than the parent molecule in lowering IOP in experimental animals. Thus, the tail conferring water solubility to such an enzyme inhibitor is more important for its topical activity as antiglaucoma drug than the heterocyclic/aromatic ring to which the sulfonamido moiety is grafted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632049     DOI: 10.1016/s0968-0896(99)00190-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  17 in total

1.  Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations.

Authors:  Jason Wagner; Balendu Sankara Avvaru; Arthur H Robbins; Andrea Scozzafava; Claudiu T Supuran; Robert McKenna
Journal:  Bioorg Med Chem       Date:  2010-06-15       Impact factor: 3.641

2.  Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Anuj Khandelwal; Wen Gu; Douglas Brown; Weiya Liu; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

3.  A class of carbonic anhydrase I - selective activators.

Authors:  Erol Licsandru; Muhammet Tanc; Istvan Kocsis; Mihail Barboiu; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2016-11-01       Impact factor: 5.051

4.  Synthesis, Anti-Breast Cancer Activity, and Molecular Docking Study of a New Group of Acetylenic Quinolinesulfonamide Derivatives.

Authors:  Krzysztof Marciniec; Bartosz Pawełczak; Małgorzata Latocha; Leszek Skrzypek; Małgorzata Maciążek-Jurczyk; Stanisław Boryczka
Journal:  Molecules       Date:  2017-02-16       Impact factor: 4.411

5.  Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]thiazole-5- and 6-sulfonamides.

Authors:  Morteza Abdoli; Andrea Angeli; Murat Bozdag; Fabrizio Carta; Ali Kakanejadifard; Hamid Saeidian; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

6.  New sulfonamides containing organometallic-acylhydrazones: synthesis, characterisation and biological evaluation as inhibitors of human carbonic anhydrases.

Authors:  Yosselin Huentupil; Luis Peña; Néstor Novoa; Emanuela Berrino; Rodrigo Arancibia; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

7.  Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies.

Authors:  Ciro Milite; Giorgio Amendola; Alessio Nocentini; Silvia Bua; Alessandra Cipriano; Elisabetta Barresi; Alessandra Feoli; Ettore Novellino; Federico Da Settimo; Claudiu T Supuran; Sabrina Castellano; Sandro Cosconati; Sabrina Taliani
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

8.  Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors.

Authors:  Mohammad M Al-Sanea; Ahmed Elkamhawy; Sora Paik; Silvia Bua; So Ha Lee; Mohamed A Abdelgawad; Eun Joo Roh; Wagdy M Eldehna; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

9.  Quinoline-8-sulfonamide.

Authors:  Krzysztof Marciniec; Andrzej Maślankiewicz; Maria Nowak; Joachim Kusz
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-09-01

10.  Inhibition of the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa with monothiocarbamates.

Authors:  Alessio Nocentini; Daniela Vullo; Sonia Del Prete; Sameh M Osman; Fatmah A S Alasmary; Zeid AlOthman; Clemente Capasso; Fabrizio Carta; Paola Gratteri; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.